Alignment Healthcare, Inc. (ALHC)
NASDAQHealth CareMedical - Healthcare PlansSnapshot 2026-10-29
$7.27-9.80%
Close 2026-10-30 · 1-day change
NASDAQHealth CareMedical - Healthcare PlansSnapshot 2026-10-29
Research Workspace
Put ALHC beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is growing steadily — about 37% over the past year.
View GrowthMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 69% in its worst 12-month stretch.
View RiskALHC’s case rests on Medicare Advantage membership growth, supported by strong recent financial performance. Revenue growth accelerated to 36.7% year over year in Q3 2026, though GAAP earnings were inline. It trades at 24× P/E versus a 23× peer median; expectations look modest versus our view. CMS rating downgrades threaten membership growth, and Medicare costs pressure profitability. Our model puts the next-quarter miss probability near 21%. Peer multiples imply a price about 23% above where it trades; our read remains intact. This read is provisional.
Trailing returns as of 2026-10-30. ALHC is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 16 analysts currently covering ALHC (as of Oct 2026).
Based on 6 Wall Street analysts offering 12-month price targets for ALHC in the last 4 months.
Continue this research
Compare ALHC with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ALHC Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 6 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Services — fair value, gap to price, and forward P/E.
Compare the value case
Put ALHC next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Grow revenue and raise full-year guidance
2027 growth target supports expansion, while lower 2026 EBITDA outlook tempers near-term performance expectations.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $7.27
The last 12 months of price, then the range of analyst 12-month targets from today’s $7.27.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Deliver profitable growth and improve operating performance
An official earnings-call transcript is material context, but the event title alone gives no results or outlook details.
Threatens: Improve adjusted gross profit and adjusted EBITDA
Quarterly loss amid lingering Medicare costs pressures profitability and adjusted earnings improvement.
Advances: Increase revenue and raise full-year guidance
Revenue beat supports growth objective, while in-line EPS offers no earnings upside.
Threatens: Increase revenue and raise full-year guidance
Price target cut indicates revenue growth concerns.
Threatens: Grow Medicare Advantage membership
CMS ratings impact Medicare Advantage membership growth.
Threatens: Grow Medicare Advantage membership
Downgrade impacts growth in Medicare Advantage membership.
Threatens: Improve adjusted gross profit and adjusted EBITDA
Cost pressures may hinder profit and EBITDA improvement.
